Navigation Links
URI scientists reveal mechanism that regulates cancer-causing gene
Date:3/26/2009

KINGSTON, R.I. March 26, 2009 Two University of Rhode Island scientists have revealed how a cancer causing protein is regulated by reactive oxygen species (ROS) -- a type of stress signal. Their findings provide new insight into how this protein normally behaves in human cells and may help in the design of drugs targeting specific cancers.

Doctoral student David J. Kemble and Professor Gongqin Sun in the URI Department of Cell and Molecular Biology are the first to provide a biochemical mechanism describing how certain protein tyrosine kinases sense and respond to oxidation. This sensing system was found to uniquely apply to two families of proteins implicated in numerous cancers: the Src and Fibroblast Growth Factor Receptor families of tyrosine kinases.

Their results were published online March 9 in the Proceedings of the National Academy of Sciences.

Src was the first enzyme identified as a cancer-causing gene in the early 1900's. For years scientists have been studying how the enzymes are expressed in cancer cells what do they do and what controls them.

According to Kemble and Sun, Src is a master regulator of cell function, controlling cell metabolism, division, and death. In normal cells, the function of Src is turned off, and it is turned on only when certain stimulatory signals activate it. When the regulatory mechanisms that control Src activity are disrupted, Src may be turned on all the time, which turns the host cell into a cancer cell. Thus, it is crucial to understand how Src function is controlled.

Reactive oxygen species have long been viewed as damaging byproducts of oxygen-based metabolism. However, it is now recognized that ROS are produced when the cells are under growth stimulation, and they in turn regulate other cellular events. Accumulating evidence indicates that ROS can directly regulate the function of Src function, and thus indirectly control many cellular processes. Y
'/>"/>

Contact: Todd McLeish
tmcleish@uri.edu
401-874-7892
University of Rhode Island
Source:Eurekalert

3

GOOD

Page: 1 2

Related medicine news :

1. Scientists ID New Biomarker for Prostate Cancer
2. Herpes: Scientists find cellular process that fights virus
3. New book chronicles the journeys of women physicians and scientists to fighting cancer
4. University of Washington scientists one step closer to stopping bone loss during spaceflight
5. New Book Chronicles the Journeys of Women Physicians and Scientists to the Front Lines of Fighting Cancer
6. Biotech company cofounded by BIDMC scientists targets natural killer T-cells
7. Scientists trial device to treat chemotherapy-related nausea
8. Scientists closer to understanding how to control high blood sugar
9. First Treatment for Muscular Dystrophy in Sight: Scientists Harness Exon-Skipping in Large Animal to Successfully Treat Duchenne Muscular Dystrophy
10. First treatment for muscular dystrophy in sight: Scientists successfully harness exon-skipping
11. Scientists find gene that modifies severity of cystic fibrosis lung disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... York (PRWEB) May 21, 2013 The ... Conserve hip replacement lawsuits in U.S. District ... in response to a request from Plaintiffs’ Counsel to ... Defendant. The May 17th Order grants that request, ... be conducted. (In re: Wright Medical Technology, Inc., Conserve ...
(Date:5/21/2013)... MedMar Healing Center announces their participation ... Food Bank. Twenty-eight businesses, including MedMar Healing Center, doctors, and ... The goal is to raise food to help area kids ... families in recent years. , “We like being able ... need,” explains Douglas Chloupek of MedMar Healing Center. “Taking part ...
(Date:5/21/2013)... Defense Serum Repository (DoDSR), University of Cincinnati (UC) researchers ... disease (IBD), which could help with earlier diagnosis and ... , This finding, the first of its kind and ... via podium presentation by staff from Walter Reed National ... held May 18-21 in Orlando, Fla. , The ...
(Date:5/21/2013)... 21, 2013 Today, Zane Benefits, Inc. ... FSA accounts. Zane Benefits, which provides comprehensive and ... the leader in defined contribution and ... , According to Zane Benefits’ website, the Affordable Care ... into law in 2010 and impacts many areas of ...
(Date:5/21/2013)... May 21, 2013 The American Diabetes ... people in the United States of America are affected ... at a great risk of developing peripheral neuropathy which ... lives. The ADA further goes on saying that the ... and around 2 million new cases are diagnosed every ...
Breaking Medicine News(10 mins):Health News:Wright Hip Lawsuit News: Bernstein Liebhard LLP Notes Issuance of New Order in Federal Wright Conserve Hip Replacement Litigation 2Health News:Wright Hip Lawsuit News: Bernstein Liebhard LLP Notes Issuance of New Order in Federal Wright Conserve Hip Replacement Litigation 3Health News:San Jose Cannabis Club Helps Feed Hungry Children with Second Harvest Food Bank 2Health News:Biomarkers discovered for inflammatory bowel disease 2Health News:Zane Benefits Publishes New Information on HRA, HSA and FSA Accounts 2Health News:Zane Benefits Publishes New Information on HRA, HSA and FSA Accounts 3Health News:Neuracel Aims to Reduce Peripheral Neuropathy Pain 2
... risk of certain types of cervical cancer. The study, ... reveals obesity and body fat //distribution are associated more ... study involved 124 women with adenocarcinoma, 139 with squamous ... control group. Adenocarcinomas involve cells from the walls of ...
... Syndrome is a severe injury to most or all of ... and often are on life support. //A new study finds ... ARDS after a trauma. ,ARDS is not a specific ... with a number of diseases including pneumonia, shock, sepsis and ...
... the larynx are diagnosed in the United States. About 5,000 ... taking away their voice box and communication, as they know ... back. ,For five years, five months and 13 days, ... forget, and that is something she says she will never ...
... who had very low birth weights are likely to ... others born at higher birth rates. //The study, conducted ... reports respiratory function is more drastically reduced with smoking ... with low birth weight, defined as weighing less than ...
... prevent bone loss may also help prevent prostate cancer from ... Kingdom indicates oral sodium clodronate may slow the spread of ... //This is a drug commonly used to prevent bone loss. ... about 85 percent of men. The researchers recruited 311 men ...
... Unlike the outbreak earlier this year, the next time ... public health systems, //says a report by the National ... chains of SARS transmission of were stopped, the virus ... to humans, the report says. ,"The wave of ...
Cached Medicine News:Health News:A voice saving surgery 2Health News:Return of SARS possible this fall 2
(Date:5/21/2013)... N.Y. , May 21, 2013 Sanofi ... (NASDAQ: REGN) today announced that the New England ... 2a study results of dupilumab (SAR231893/REGN668) in patients with ... targeting the alpha subunit of the interleukin 4 receptor ... IL-13, drivers of Th2 (Type 2 helper T cell) ...
(Date:5/21/2013)... May 21, 2013 U.S. spending on specialty ... diseases such as cancer, multiple sclerosis and rheumatoid arthritis ... end of 2015, according to a forecast released today ... http://photos.prnewswire.com/prnh/20080827/EXPRESSSCRIPTSLOGO ) "As we see ... health plans to act so they can continue to ...
(Date:5/21/2013)... CITY, Calif. , May 21, 2013 ... ACRX ), a specialty pharmaceutical company focused ... therapies for the treatment of acute and ... that in a placebo-controlled Phase 3 study ... (patient-controlled analgesia) System (NanoTab System), the primary ...
Breaking Medicine Technology:Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 2Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 3Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 4Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 5Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 6Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 7U.S. Spending on Specialty Medications Likely to Increase 67 Percent Through 2015 2U.S. Spending on Specialty Medications Likely to Increase 67 Percent Through 2015 3U.S. Spending on Specialty Medications Likely to Increase 67 Percent Through 2015 4U.S. Spending on Specialty Medications Likely to Increase 67 Percent Through 2015 5Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 2Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 3Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 4Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 5Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 6Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 7Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 8Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 9Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 10
...
Conforms to the convexity of the lens providing easier access to anterior capsule. Reduces pontential of corneal touch. 35G x 5/8in (.50 x 16mm)...
Conforms to the convexity of the lens providing easier access to anterior capsule. Reduces pontential of corneal touch. 25G x 5/8in (.50 x 16mm)...
... Unique product designed for LASIK surgery ... Designed to irrigate the corneal interface ... easy insertion under the flap and ... ports provide multi-directional irrigation.27G x 7/8in ...
Medicine Products: